anonymous
Guest
anonymous
Guest
In the end we in the field are accountable for ourselves. However management has yet to be accountable for ANYTHING. Is it any wonder why Mydayis is not performing well nationally. This was the worst launch of a product in the history of pharma. I never expect everything to be perfect but I also never anticipate everything being a complete disaster either. Here are a few ideas that could help besides all of upper management getting into a boat and heading out to sea. Pay us for launching a drug, don’t stack rank territories, understand that small rural territories cannot create the same volume as urban areas. Understand that we have two meds that do the same thing and both meds would be used for the same patient..so the goals for Vyvanse should not be astronomical when again we are competing against ourselves. $15 are you fucking kidding me!!! Xiidra reps were making a killing during the launch so why not make it equitable for the NBU. Understand that we literally have to hold the patients hand to get scripts through at the pharmacy. So instead of blaming rd’s and the sales force take an objective look at everything you morons have done with this launch and really try and think if maybe you are to blame for EVERYTHING, and then open more champagne bottles and take those corks and shove them up your asses.
Mydayis was an act of desperation. There was a reason the prior leadership didn’t bother with it —-it offers no real advantage and as soon as Vyvanse goes generic why would anyone pay more for it. Our moron CEO thought it would make a “spin-off” more appealing to some buyer. But that would have required Flemming finding a CEO dumber than him and clearly he is at the bottom of the IQ barrel.